AmEx Pharmacy announced a voluntary recall of one lot of bevacizumab due to a reported defective delivery system, according to a press release.
The Monoject syringe may be difficult to express, and the force needed to express bevacizumab (Avastin, Genentech) could potentially result in damage to the eye. Three reports of the lot being difficult to express, two resulting in adverse drug events, have been reported.
The affected lot is 190212AB, BUD 5/13/2019, and it was distributed to ophthalmologist clinics in Pennsylvania, Illinois, Texas, Wisconsin, Kansas, Tennessee, Indiana and Arizona.
AmEx
Uncategorized